Christopher Pole, MD
Ophthalmology · Overland Park, KSNPI 1285883231
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $121,740 of the $128,530 with a category attached, or 94.7%. Microsurgical Technology, Inc. accounts for 75.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $73,698 and has fallen 86.9% since, to $9,651 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $952.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$96K
- Rxsight Inc$28K
- Glaukos Corporation$1K
- Alcon$1K
- The Cameron-ehlen Group, Inc.$495
- AbbVie$216
- plus $1K from 14 others
Across 2 payments — averaging $51,761 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$104K
What the payments were for
- Consulting fees$121,74095%
- Speaking & faculty fees$260%
- Travel & lodging$7441%
- Food & beverage$6,0025%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 6 | $96,406 |
| Rxsight Inc | 33 | $27,891 |
| Glaukos Corporation | 14 | $1,271 |
| Alcon | 33 | $1,133 |
| The Cameron-ehlen Group, Inc. | 12 | $495 |
| AbbVie(2 entities) | 9 | $216 |
| Aerie Pharmaceuticals, Inc. | 3 | $147 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $133 |
| Amgen(2 entities) | 2 | $133 |
| Ocular Therapeutix, Inc. | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 1 | $103 |
| Sun Pharmaceutical Industries Inc. | 5 | $98 |
| Harrow Eye, LLC | 3 | $92 |
| Beaver-visitec International, Inc. | 1 | $71 |
| Bausch & Lomb Americas Inc. | 2 | $67 |
| Sight Sciences, Inc. | 3 | $54 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT INJECTOR HANDPIECE$27,246
- RXSIGHT CONTACT LENS$27,246
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$27,246
- RXSIGHT INJECTOR CARTRIDGE$27,246
- LIGHT ADJUSTABLE LENS (LAL)$16,039
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$11,207
- Tecnis IOL$448
- Ophthalmic Surgical Adjuncts$375
- iStent Trabecular Micro-Bypass Stent System$263
- iStent inject Trabecular Micro-Bypass Stent System$263
- Clareon$262
- Rocklatan$241
- HEALON PRO$149
- Tecnis Simplicity$149
- DEXTENZA$125
- iStent Infinite$124
- iDoseTR$124
- Rhopressa$122
- TEPEZZA$116
- iStent$114
How this compares
$128,530 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 51 | $74,752 |
| LumiganBimatoprost | 79 | $36,506 |
| Prednisolone Acetate | 574 | $21,730 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $11,192 |
| Ketorolac Tromethamine | 363 | $9,357 |
| Cyclosporine | 17 | $8,956 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 51 | $5,794 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,589 |
| Ofloxacin | 346 | $3,707 |
| Latanoprost | 288 | $3,189 |
| Travoprost | 12 | $2,261 |
| Loteprednol Etabonate | 19 | $1,879 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 95 | $1,538 |
| Dorzolamide Hcl | 48 | $914 |
| Timolol Maleate | 63 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $216 | $122,450170 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $147 | $4,58913 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $48 | $1,87919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Jason StahlOverland Park$10K
- Christopher KetchersideOverland Park$6K
- Selena FuOverland Park$5K
- Timothy CavanaughOverland Park$5K
- Johann OhlyOverland Park$4K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.